Clinical Trials
6 trialsNCT04005690 2026-02-27
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT05549661 2026-02-23
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Mayo Clinic
Phase 1 Recruiting
NCT05383196 2026-02-11
Onvansertib + Paclitaxel In TNBC
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT05450965 2025-12-17
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
Phase 2 Recruiting
NCT06736717 2025-02-06
PANCONVA
University of Kansas Medical Center
Phase 1/2 Recruiting
NCT06398587 2024-07-19
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn